Ketrosden Triasmitra Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Ketrosden Triasmitra Tbk. trades at Rp955 (market cap 2.64T, 92.24M 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Ketrosden Triasmitra Tbk. is far larger — about 25.3× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| KETR | SCPI | |
|---|---|---|
Market Cap | 2.64T | 104.4B |
Volume | 92.24M | — |
Lot | 922.38K | — |
Turnover | 90.37B | — |
Average Price | 979.8 | — |
Value | 90.37B | — |
Indicative Equilibrium Price | 955 | — |
Indicative Equilibrium Volume | 29.3K | — |
Trailing returns across standard periods
Latest headlines on both assets
PT Ketrosden Triasmitra Tbk was established base on Notarial Deed No.179 of Pudji Redjeki Irawati S.H., dated November 25, 1994.
Read more on KETR →PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →